
Bio-Rad Laboratories BIO
$ 288.21
0.14%
Quarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Accounts Receivables 2011-2026 | BIO
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 452 M | 489 M | 495 M | 424 M | 419 M | 393 M | 392 M | 465 M | 372 M | 391 M | 378 M | 423 M | 399 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 495 M | 372 M | 422 M |
Quarterly Accounts Receivables Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 470 M | 425 M | 462 M | 446 M | 445 M | 457 M | 492 M | 498 M | 495 M | 432 M | - | 464 M | 424 M | 418 M | 399 M | 408 M | 419 M | 419 M | 419 M | 419 M | 393 M | 393 M | 393 M | 393 M | 392 M | 392 M | 392 M | 392 M | 465 M | 465 M | 465 M | 465 M | 372 M | 372 M | 372 M | 372 M | 391 M | 391 M | 391 M | 391 M | 378 M | 378 M | 378 M | 378 M | 423 M | 423 M | 423 M | 423 M | 399 M | 399 M | 399 M | 399 M | 399 M | 375 M | 395 M | 389 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 498 M | 372 M | 415 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AdaptHealth Corp.
AHCO
|
371 M | $ 13.18 | 2.93 % | $ 1.78 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
LivaNova PLC
LIVN
|
216 M | $ 63.36 | -1.31 % | $ 3.46 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 5.15 | 1.18 % | $ 61.6 M | ||
|
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.26 | -0.79 % | $ 51.3 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
161 M | $ 188.66 | -0.47 % | $ 13.3 B | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.61 | -2.87 % | $ 38 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.22 | -0.16 % | $ 121 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 11.1 | -5.77 % | $ 314 M | ||
|
Globus Medical
GMED
|
679 M | $ 93.88 | -1.04 % | $ 12.7 B | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.41 | -2.43 % | $ 6.68 M | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 2.13 | -1.16 % | $ 1.29 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
24.7 M | $ 26.16 | -0.87 % | $ 221 M | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Stryker Corporation
SYK
|
4.04 B | $ 329.07 | 0.48 % | $ 126 B | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.84 | -2.16 % | $ 372 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 5.46 | 2.25 % | $ 1.16 B | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 10.81 | -0.28 % | $ 387 M | ||
|
Varex Imaging Corporation
VREX
|
157 M | $ 12.68 | 1.2 % | $ 525 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.08 | 1.89 % | $ 18.3 M | ||
|
Vivos Therapeutics
VVOS
|
1.58 M | $ 0.88 | 4.9 % | $ 9.04 M | ||
|
CONMED Corporation
CNMD
|
248 M | $ 38.03 | -0.81 % | $ 1.18 B | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 54.63 | -2.98 % | $ 1.6 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 85.21 | -0.94 % | $ 2.96 B | ||
|
PAVmed
PAVM
|
15 K | $ 8.53 | -5.22 % | $ 5.72 M | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
660 M | $ 84.54 | 0.34 % | $ 49.4 B | ||
|
MiMedx Group
MDXG
|
75.7 M | $ 3.36 | -2.19 % | $ 497 M |